{"id":"rosuvastatin-pantoprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosuvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and cardiovascular risk. Pantoprazole is a proton pump inhibitor that suppresses gastric acid production, protecting the gastrointestinal tract. This fixed-dose combination addresses both lipid management and GI protection in patients at cardiovascular risk who may require acid suppression.","oneSentence":"This combination drug lowers cholesterol via HMG-CoA reductase inhibition (rosuvastatin) while reducing gastric acid secretion via proton pump inhibition (pantoprazole).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:06:06.922Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia with concurrent need for gastric acid suppression"},{"name":"Cardiovascular risk reduction in patients requiring proton pump inhibitor therapy"}]},"trialDetails":[{"nctId":"NCT05893849","phase":"","title":"Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-03-28","conditions":"Aging","enrollment":624},{"nctId":"NCT00930670","phase":"PHASE4","title":"Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects","status":"COMPLETED","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2009-06","conditions":"Coronary Artery Disease","enrollment":320},{"nctId":"NCT01146483","phase":"PHASE1","title":"Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2010-04","conditions":"Drug Interaction Potentiation","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rosuvastatin-pantoprazole","genericName":"Rosuvastatin-pantoprazole","companyName":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","companyId":"centre-de-recherche-de-l-institut-universitaire-de-cardiologie-et-de-pneumologie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug lowers cholesterol via HMG-CoA reductase inhibition (rosuvastatin) while reducing gastric acid secretion via proton pump inhibition (pantoprazole). Used for Hypercholesterolemia with concurrent need for gastric acid suppression, Cardiovascular risk reduction in patients requiring proton pump inhibitor therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}